Log in

NASDAQ:HOTH - Hoth Therapeutics Stock Price, Forecast & News

-0.05 (-1.02 %)
(As of 01/27/2020 06:00 AM ET)
Today's Range
Now: $4.86
50-Day Range
MA: $5.18
52-Week Range
Now: $4.86
Volume14,162 shs
Average Volume31,151 shs
Market Capitalization$49.18 million
P/E RatioN/A
Dividend YieldN/A
Hoth Therapeutics, Inc., a development stage biopharmaceutical company, focuses on developing targeted therapeutics for atopic dermatitis. It intends to use the BioLexa Platform to develop 2 topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures. The company was incorporated in 2017 and is based in New York.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:HOTH



Sales & Book Value

Annual SalesN/A


Net Income$-2,500,000.00


Market Cap$49.18 million
Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable

Receive HOTH News and Ratings via Email

Sign-up to receive the latest news and ratings for HOTH and its competitors with MarketBeat's FREE daily newsletter.

Hoth Therapeutics (NASDAQ:HOTH) Frequently Asked Questions

What is Hoth Therapeutics' stock symbol?

Hoth Therapeutics trades on the NASDAQ under the ticker symbol "HOTH."

How were Hoth Therapeutics' earnings last quarter?

Hoth Therapeutics Inc (NASDAQ:HOTH) released its earnings results on Tuesday, November, 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.07. View Hoth Therapeutics' Earnings History.

When is Hoth Therapeutics' next earnings date?

Hoth Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Hoth Therapeutics.

What price target have analysts set for HOTH?

2 brokers have issued 12-month price targets for Hoth Therapeutics' shares. Their forecasts range from $10.00 to $10.00. On average, they anticipate Hoth Therapeutics' share price to reach $10.00 in the next twelve months. This suggests a possible upside of 105.8% from the stock's current price. View Analyst Price Targets for Hoth Therapeutics.

What is the consensus analysts' recommendation for Hoth Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hoth Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hoth Therapeutics.

Has Hoth Therapeutics been receiving favorable news coverage?

Press coverage about HOTH stock has trended somewhat negative on Monday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Hoth Therapeutics earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Hoth Therapeutics.

Are investors shorting Hoth Therapeutics?

Hoth Therapeutics saw a drop in short interest during the month of January. As of January 15th, there was short interest totalling 38,300 shares, a drop of 11.3% from the December 31st total of 43,200 shares. Based on an average daily volume of 26,400 shares, the short-interest ratio is presently 1.5 days. Approximately 0.9% of the shares of the company are sold short. View Hoth Therapeutics' Current Options Chain.

Who are some of Hoth Therapeutics' key competitors?

What other stocks do shareholders of Hoth Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hoth Therapeutics investors own include Verizon Communications (VZ), General Motors (GM), NovaBay Pharmaceuticals (NBY), Cronos Group (CRON), Huntington Bancshares (HBAN), Inovio Pharmaceuticals (INO), Inseego (INSG), Novavax (NVAX), Sesen Bio (SESN) and Chesapeake Energy (CHK).

Who are Hoth Therapeutics' key executives?

Hoth Therapeutics' management team includes the folowing people:
  • Mr. Robb Knie, Pres, CEO & Director (Age 50)
  • Mr. David S. Briones, Chief Financial Officer (Age 43)
  • Ms. Jane H. Behrmann, VP of Operations (Age 34)

When did Hoth Therapeutics IPO?

(HOTH) raised $8 million in an IPO on Friday, February 15th 2019. The company issued 1,300,000 shares at $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO.

How do I buy shares of Hoth Therapeutics?

Shares of HOTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Hoth Therapeutics' stock price today?

One share of HOTH stock can currently be purchased for approximately $4.86.

How big of a company is Hoth Therapeutics?

Hoth Therapeutics has a market capitalization of $49.18 million. The company earns $-2,500,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Hoth Therapeutics employs 2 workers across the globe.View Additional Information About Hoth Therapeutics.

What is Hoth Therapeutics' official website?

The official website for Hoth Therapeutics is http://www.hoththerapeutics.com/.

How can I contact Hoth Therapeutics?

Hoth Therapeutics' mailing address is 1 Rockefeller Plaza Suite 1039, New York NY, 10020. The company can be reached via phone at 646-756-2997 or via email at [email protected]

MarketBeat Community Rating for Hoth Therapeutics (NASDAQ HOTH)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  50 (Vote Outperform)
Underperform Votes:  59 (Vote Underperform)
Total Votes:  109
MarketBeat's community ratings are surveys of what our community members think about Hoth Therapeutics and other stocks. Vote "Outperform" if you believe HOTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HOTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/27/2020 by MarketBeat.com Staff

Featured Article: Rule of 72

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel